[Antineoplastic oral agents and drug-nutrient interactions: a sistematic review].

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Nutrición Hospitalaria

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 19721898
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

  2008cited by this paper
• Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.

  2007cited by this paper
• Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

  2007cited by this paper
• Scientific perspectives on drug transporters and their role in drug interactions.

  2006cited by this paper
• Drug interactions in cancer therapy

  2006cited by this paper
• Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

  2006cited by this paper
• Parenteral nutrition safe practices: results of the 2003 American Society for Parenteral and Enteral Nutrition survey.

  2006cited by this paper
• Dissemination of the Canadian clinical practice guidelines for nutrition support: Results of a cluster randomized controlled trial

  2006cited by this paper
• A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer

  2006cited by this paper
• Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors

  2006cited by this paper
• Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

  2005cited by this paper
• Clinical Pharmacokinetics of Imatinib

  2005cited by this paper
• A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.

  2005cited by this paper
• Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies

  2005cited by this paper
• Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

  2005cited by this paper
• Single-Dose Clinical Pharmacokinetic Studies of Gefitinib

  2005cited by this paper
• An Approach to Evaluating Drug‐Nutrient Interactions

  2005cited by this paper
• The effect of food on oral melphalan absorption

  2004cited by this paper
• Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents

  2004cited by this paper
• Effect of food on pharmacokinetics of chlorambucil and its main metabolite, phenylacetic acid mustard

  2004cited by this paper
• Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

  2004cited by this paper
• The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors

  2004cited by this paper
• Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma

  2004cited by this paper
• Impairment of estramustine phosphate absorption by concurrent intake of milk and food

  2004cited by this paper
• The effect of nateglinide taken with food on gastric emptying rates in healthy subjects.

  2003cited by this paper
• The effects of food on the pharmacokinetic profile of oral vinorelbine

  2002cited by this paper
• Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil

  2002cited by this paper
• Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.

  2002cited by this paper
• Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

  2001cited by this paper
• Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.

  2001cited by this paper
• Effect of a high‐fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women

  2000cited by this paper
• Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.

  2000cited by this paper
• Assessment of Healthcare Professionals’ Knowledge About Warfarin-Vitamin K Drug-Nutrient Interactions

  2000cited by this paper
• Oral topotecan: bioavailability and effect of food co-administration

  1999cited by this paper
• Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days.

  1999cited by this paper
• Drug and diet interactions: avoiding therapeutic paralysis.

  1998cited by this paper
• Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.

  1998cited by this paper
• Oral chemotherapy: rationale and future directions.

  1998cited by this paper
• COMPARATIVE BIOAVAILABILITY OF LETROZOLE UNDER FED AND FASTING CONDITIONS IN 12 HEALTHY SUBJECTS AFTER A 2·5 MG SINGLE ORAL ADMINISTRATION

  1997cited by this paper
• THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF THE BICALUTAMIDE (‘CASODEX’) ENANTIOMERS

  1997cited by this paper
• Attitudes of Healthcare Professionals toward Patient Counseling on Drug-Nutrient Interactions

  1994cited by this paper
• On the bioavailability of 2-chloro-2′-deoxyadenosine (CdA)

  1993cited by this paper

• No citing papers are available for this paper.